Passage BIO, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)

About Passage BIO, Inc.

Passage Bio, Inc. (NASDAQ: PASG) is a United States-based clinical-stage genetic medicines company headquartered in Philadelphia, Pennsylvania. Founded in July 2017, the company focuses on developing one-time, disease-modifying therapies aimed at the underlying biology of neurodegenerative disorders. For investors, Passage Bio remains a high-risk, development-stage biotechnology name with no meaningful commercial revenue to date and a business model still centered on clinical execution, regulatory milestones, and external funding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf)) The company’s origins are closely tied to its research and collaboration framework with the University of Pennsylvania’s Gene Therapy Program, which helped establish Passage Bio’s scientific base and early pipeline. This collaboration was originally built around rare, monogenic central nervous system diseases and later supported the company’s broader push into neurodegenerative indications. That historical tie remains important because it underpins Passage Bio’s access to scientific know-how and gene therapy expertise. ([nasdaq.com](https://www.nasdaq.com/press-release/passage-bio-announces-expansion-of-gene-therapy-collaboration-with-university-of)) Passage Bio’s lead clinical asset is PBFT02, a candidate being developed for frontotemporal dementia, including FTD associated with progranulin deficiency. The company describes the mechanism as raising progranulin levels to restore lysosomal function and potentially slow disease progression. Strategically, this places Passage Bio in a highly specialized segment of the CNS biotech market where scientific differentiation matters, but where clinical and regulatory risk is also substantial. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf)) From a competitive standpoint, Passage Bio is not yet a commercial-stage peer and does not compete on scale, sales infrastructure, or diversified product revenue. Instead, its value proposition rests on pipeline optionality, platform credibility, and the potential to advance a small number of genetically targeted programs into later-stage development. SEC filings show recurring losses, a large accumulated deficit, and continuing dependence on equity financings, collaborations, and licensing arrangements to fund operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf)) Recent developments have been notable. The company reported updated interim data from the upliFT-D trial and stated that a strategic review is underway; it also disclosed that Wedbush PacGrow has been engaged as financial advisor for that process. Passage Bio has continued to present at investor conferences in 2025 and 2026, reflecting ongoing capital-markets engagement while it works through clinical, regulatory, and corporate priorities. For U.S. investors following insider activity, this NASDAQ-listed name remains a speculative biotech story where execution, financing flexibility, and readouts on PBFT02 are the key drivers. ([nasdaq.com](https://www.nasdaq.com/press-release/passage-bio-reports-updated-interim-data-uplift-d-trial-and-provides-regulatory-and))